• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Aildenafil Citrate Tablets
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen

Orchid Pharma gets EIR from US FDA

expressbpdJanuary 09, 2018

Tag: FDA , Orchid Pharma

Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility. The company has received the EIR from the United States Food and Drug Administration (US FDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.

The facility was inspected by US FDA in the month of June, 2017, it added. As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

Previous:VSASL imaging can detect placental perfusion abnormalities in foetal CHD

Next:FDA grants fast-track designation to malaria drug Tafenoquine

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Orchid Pharma gets EIR from US FDA | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

Ifosfamide (FDA)

Ifosfamide (FDA)
Praziquantel (FDA)

Praziquantel (FDA)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Lincomycin HCL (FDA)

Lincomycin HCL (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service